# Avacta Group agreement with Astrea Bioseparations ‘the perfect deal’ (Interview)

- Link: https://www.directorstalkinterviews.com/avacta-group-agreement-with-astrea-bioseparations-%e2%80%98the-perfect-deal%e2%80%99/412949846
- Published: 2020-12-22T07:29:56+00:00
- Author: Giles

**[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
Group plc** ([LON:AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l))
CEO Alastair Smith joins DirectorsTalk to discuss the agreement with Astrea Bioseparations.
Alastair explains what affinity separation is, tell us about the market, the details
of the deal, how it fits in with the company strategy, other opportunities and progress
with the SARS-CoV-2 rapid antigen test.

Avacta Group is developing novel cancer immunotherapies combining its two proprietary
platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy.
With this approach, the Company aims to address the lack of a durable response to
current immunotherapies experienced by most patients. The Company’s therapeutics
development activities are based in Cambridge, UK.

The Company benefits from near-term revenues generated from Affimer reagents for
diagnostics, bioprocessing and research, through a separate business unit based 
in Wetherby, UK.

Share on: